Advanced tools are being deployed by Duke Health and others in the fight against vision loss. STORY HIGHLIGHTS Half of ...

The acquisition strengthens Bausch + Lomb's existing portfolio of surgical and pharmaceutical glaucoma treatments.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

What’s normal ‘wear and tear’ due to age, and what’s something more serious? Here's how to tell if vision loss is normal or ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

Bausch + Lomb Corporation (BLCO) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Bausch + Lomb (BLCO) announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, the first clinically validated, ...

NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a biopharmaceutical company ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...